Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines shares outstanding 2017–2026What are shares outstanding? Shares outstanding are all the shares a company has issued that investors hold, insiders included. Their number times the share price is the market value.
Revolution Medicines had 216,292,000 shares outstanding on 13 November 2026. Revolution Medicines had 203.52M diluted shares on average over the last twelve months, up 11.0% on the twelve months before. In fiscal year 2025 the average was 190.13M.
Last updated 8 Nov 2026 · Next report 24 Feb 2027
Shares outstanding
Change on the year
| Fiscal year | Period ending | Shares outstanding | Change on the year | Basic shares |
|---|---|---|---|---|
| TTM | 30 Sept 2026 | 203.52M | +11.02% | 203.52M |
| FY2025 | 31 Dec 2025 | 190.13M | +13.35% | 190.13M |
| FY2024 | 31 Dec 2024 | 167.74M | +48.24% | 167.74M |
| FY2023 | 31 Dec 2023 | 113.15M | +40.34% | 113.15M |
| FY2022 | 31 Dec 2022 | 80.63M | +10.74% | 80.63M |
| FY2021 | 31 Dec 2021 | 72.81M | +9.32% | 72.81M |
| FY2020 | 31 Dec 2020 | 66.60M | +82.60% | 66.60M |
| FY2019 | 31 Dec 2019 | 36.47M | 0.00% | 36.47M |
| FY2018 | 31 Dec 2018 | 36.47M | 0.00% | 36.47M |
| FY2017 | 31 Dec 2017 | 36.47M | — | 36.47M |
| Quarter | Period ending | Shares outstanding | Growth on a year before | Basic shares |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 214.95M | +13.59% | 214.95M |
| Q2 FY2026 | 30 Jun 2026 | 210.89M | +12.09% | 210.89M |
| Q1 FY2026 | 31 Mar 2026 | 198.10M | +5.29% | 198.10M |
| Q4 FY2025 | 31 Dec 2025 | 190.13M | +13.35% | 190.13M |
| Q3 FY2025 | 30 Sept 2025 | 189.23M | +13.42% | 189.23M |
| Q2 FY2025 | 30 Jun 2025 | 188.15M | +13.93% | 188.15M |
| Q1 FY2025 | 31 Mar 2025 | 188.15M | +14.22% | 188.15M |
| Q4 FY2024 | 31 Dec 2024 | 167.74M | +18.81% | 167.74M |
| Q3 FY2024 | 30 Sept 2024 | 166.84M | +52.74% | 166.84M |
| Q2 FY2024 | 30 Jun 2024 | 165.14M | +54.51% | 165.14M |
| Q1 FY2024 | 31 Mar 2024 | 164.73M | +73.71% | 164.73M |
| Q4 FY2023 | 31 Dec 2023 | 141.18M | +58.35% | 141.18M |
| Q3 FY2023 | 30 Sept 2023 | 109.23M | +28.97% | 109.23M |
| Q2 FY2023 | 30 Jun 2023 | 106.88M | +43.89% | 106.88M |
| Q1 FY2023 | 31 Mar 2023 | 94.83M | +27.87% | 94.83M |
| Q4 FY2022 | 31 Dec 2022 | 89.16M | +20.76% | 89.16M |
| Q3 FY2022 | 30 Sept 2022 | 84.69M | +15.18% | 84.69M |
| Q2 FY2022 | 30 Jun 2022 | 74.28M | +1.20% | 74.28M |
| Q1 FY2022 | 31 Mar 2022 | 74.16M | +5.31% | 74.16M |
| Q4 FY2021 | 31 Dec 2021 | 73.83M | +11.33% | 73.82M |
| Q3 FY2021 | 30 Sept 2021 | 73.54M | +13.32% | 73.54M |
| Q2 FY2021 | 30 Jun 2021 | 73.40M | +24.93% | 73.40M |
| Q1 FY2021 | 31 Mar 2021 | 70.42M | +140.36% | 70.42M |
| Q4 FY2020 | 31 Dec 2020 | 66.32M | +81.83% | 66.32M |
| Q3 FY2020 | 30 Sept 2020 | 64.89M | +77.92% | 64.89M |
| Q2 FY2020 | 30 Jun 2020 | 58.75M | +61.08% | 58.75M |
| Q1 FY2020 | 31 Mar 2020 | 29.30M | -19.67% | 29.30M |
| Q4 FY2019 | 31 Dec 2019 | 36.47M | 0.00% | 36.47M |
| Q3 FY2019 | 30 Sept 2019 | 36.47M | — | 36.47M |
| Q2 FY2019 | 30 Jun 2019 | 36.47M | — | 36.47M |
| Q1 FY2019 | 31 Mar 2019 | 36.47M | — | 36.47M |
| Q4 FY2018 | 31 Dec 2018 | 36.47M | — | 36.47M |
Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
See also:Revenue,Net income,EPS,Operating income,Cash on hand,Total debt,Free cash flow,Income statement
Common questions about Revolution Medicines's shares
Source: Financial Modeling PrepVerified against SEC filings